tacrolimus + placebo

Phase 3Completed

0 views this week 0 watching⚡ Active

Interest: 40/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

✓

Phase 2

Phase 3

Approved

Indication / Disease

Myasthenia Gravis

Conditions

Myasthenia Gravis

Trial Timeline

Apr 1, 2006 → Jun 1, 2008

NCT ID

NCT00309088

About tacrolimus + placebo

tacrolimus + placebo is a phase 3 stage product being developed by Astellas Pharma for Myasthenia Gravis. The current trial status is completed. This product is registered under clinical trial identifier NCT00309088. Target conditions include Myasthenia Gravis.

What happened to similar drugs?

1 of 20 similar drugs in Myasthenia Gravis were approved

Approved (1) Terminated (2) Active (17)

❌SatralizumabChugai PharmaceuticalPhase 3

🔄tacrolimusAstellas PharmaPhase 3

🔄Tacrolimus capsule + PlaceboAstellas PharmaPhase 3

🔄Cladribine Low Dose + Cladribine High DoseMerckPhase 3

🔄Remibrutinib (Blinded) + Remibrutinib (Open Label)NovartisPhase 3

🔄IptacopanNovartisPhase 3

🔄mycophenolate mofetil [CellCept] + PlaceboRochePhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (5)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01224028	Phase 2	Completed	Nov 1, 2010	Jun 1, 2011	IgA Nephropathy
NCT00347048	Phase 3	Completed	Sep 1, 2006	Apr 1, 2008	Ulcerative Colitis
NCT00319917	Approved	Completed	Apr 1, 2006	Oct 1, 2008	Rheumatoid Arthritis
NCT00309088	Phase 3	Completed	Apr 1, 2006	Jun 1, 2008	Myasthenia Gravis
NCT00106392	Approved	Completed	Feb 1, 2005	Nov 1, 2008	Erectile Dysfunction

Competing Products

20 competing products in Myasthenia Gravis

See all competitors

Product	Company	Stage	Hype Score
Satralizumab	Chugai Pharmaceutical	Phase 3	32
tacrolimus	Astellas Pharma	Phase 3	40
Tacrolimus capsule + Placebo	Astellas Pharma	Phase 3	40
Ravulizumab	AstraZeneca	Pre-clinical	33
Cladribine Low Dose + Cladribine High Dose	Merck	Phase 3	47
Remibrutinib (Blinded) + Remibrutinib (Open Label)	Novartis	Phase 3	47
Placebo + CFZ533	Novartis	Phase 2	35
Iptacopan	Novartis	Phase 3	47
mycophenolate mofetil [CellCept] + Placebo	Roche	Phase 3	40
mycophenolate mofetil (CellCept) + placebo	Roche	Phase 3	40
inebilizumab + IV Placebo	Amgen	Phase 3	44
Inebilizumab	Amgen	Phase 2	42
Abatacept Injection	Bristol Myers Squibb	Phase 1	21
Tolebrutininb + Placebo	Sanofi	Phase 3	32
Pozelimab + Cemdisiran + Cemdisiran + Pozelimab	Regeneron Pharmaceuticals	Phase 3	44
HIZENTRA ®	CSL	Phase 2	35
Subcutaneous immunoglobulins	CSL	Phase 1	21
Human normal immunoglobulin G (IgG)	CSL	Phase 3	40
zilucoplan (RA101495)	UCB	Phase 3	44
zilucoplan (RA101495) + Placebo	UCB	Phase 2	35